BACKGROUND: Vaccine efficacy (VE) assessed in a randomized controlled clinical trial can be affected by demographic, clinical, and other subject-specific characteristics evaluated as baseline covariates. Understanding the effect of covariates on efficacy is key to decisions by vaccine developers and public health authorities. METHODS: This work evaluates the impact of including correlate of protection (CoP) data in logistic regression on its performance in identifying statistically and clinically significant covariates in settings typical for a vaccine phase 3 trial. The proposed approach uses CoP data and covariate data as predictors of clinical outcome (diseased versus non-diseased) and is compared to logistic regression (without CoP data) to relate vaccination status and covariate data to clinical outcome. RESULTS: Clinical trial simulations, in which the true relationship between CoP data and clinical outcome probability is a sigmoid function, show that use of CoP data increases the positive predictive value for detection of a covariate effect. If the true relationship is characterized by a decreasing convex function, use of CoP data does not substantially change positive or negative predictive value. In either scenario, vaccine efficacy is estimated more precisely (i.e., confidence intervals are narrower) in covariate-defined subgroups if CoP data are used, implying that using CoP data increases the ability to determine clinical significance of baseline covariate effects on efficacy. CONCLUSIONS: This study proposes and evaluates a novel approach for assessing baseline demographic covariates potentially affecting VE. Results show that the proposed approach can sensitively and specifically identify potentially important covariates and provides a method for evaluating their likely clinical significance in terms of predicted impact on vaccine efficacy. It shows further that inclusion of CoP data can enable more precise VE estimation, thus enhancing study power and/or efficiency and providing even better information to support health policy and development decisions.

1st Faculty of Medicine Charles University Prague Czech Republic

Quantitative Pharmacology and Pharmacometrics Merck and Co Inc Rahway NJ USA

Quantitative Pharmacology and Pharmacometrics MSD Czech Republic Svornosti 3321 2 150 00 Prague 5 Prague Czech Republic

Statistical Modelling Institute of Computer Science of the Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Halloran ME, Longini IM, Struchiner CJ. Design and Analysis of Vaccine Studies. New York: Springer; 2010. pp. 1–18.

Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–1416. doi: 10.1016/S0140-6736(21)02183-8. PubMed DOI PMC

Piché-Renaud P-P, Swayze S, Buchan SA, et al. COVID-19 Vaccine Effectiveness Against Omicron Infection and Hospitalization. Pediatrics. 2023;151(4):e2022059513. doi: 10.1542/peds.2022-059513. PubMed DOI

Blanquart F, Abad C, Ambroise J, et al. Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022. Int J Infect Dis. 2023;133:89–96. doi: 10.1016/j.ijid.2023.04.410. PubMed DOI PMC

Deputy NP, Deckert J, Chard AN, et al. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. New Engl J Med. 2023;388:2434–2443. doi: 10.1056/NEJMoa2215201. PubMed DOI PMC

Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Plotkin’s Vaccines. Amsterdam: Elsevier; 2017.

Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–440. doi: 10.1002/sim.4780080407. PubMed DOI

Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081–1085. doi: 10.1097/INF.0b013e3182367662. PubMed DOI

Habib MA, Prymula R, Carryn S, et al. Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine. 2021;39:3445–3454. doi: 10.1016/j.vaccine.2021.02.074. PubMed DOI

Salje H, Alera MT, Chua MN, et al. Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nat Med. 2021;27:1395–1400. doi: 10.1038/s41591-021-01392-9. PubMed DOI PMC

Danier J, Callegaro A, Soni J, et al. Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction-Confirmed Influenza Illness in Children 6–35 Months of Age: Statistical Evaluation of a Correlate of Protection. Open Forum Infect Dis. 2022;9(2):ofab477. doi: 10.1093/ofid/ofab477. PubMed DOI PMC

Dudasova J, Laube R, Valiathan C, et al. A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. NPJ Vaccines. 2021;6(1):133. doi: 10.1038/s41541-021-00377-6. PubMed DOI PMC

Genser B, Cooper PJ, Yazdanbakhsh M, Barreto ML, Rodrigues LC. A guide to modern statistical analysis of immunological data. BMC Immunol. 2007;8:27. doi: 10.1186/1471-2172-8-27. PubMed DOI PMC

Xu XS, Yuan M, Zhu H, et al. Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity. Br J Clin Pharmacol. 2018;84(7):1525–1534. doi: 10.1111/bcp.13577. PubMed DOI PMC

Dunning AJ. A model for immunological correlates of protection. Stat Med. 2006;25(9):1485–1497. doi: 10.1002/sim.2282. PubMed DOI

Coudeville L, Andre P, Bailleux F, Weber F, Plotkin SA. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin. 2010;6(10):841–848. doi: 10.4161/hv.6.10.12636. PubMed DOI PMC

Callegaro A, Tibaldi F. Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy. BMC Med Res Methodol. 2019;19:47. doi: 10.1186/s12874-019-0687-y. PubMed DOI PMC

Dunning AJ, Kensler J, Coudeville L, Bailleux F. Some extensions in continuous models for immunological correlates of protection. BMC Med Res Methodol. 2015;15:107. doi: 10.1186/s12874-015-0096-9. PubMed DOI PMC

Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M. Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol. 2009;169(11):1398–1405. doi: 10.1093/aje/kwp055. PubMed DOI PMC

Noma H, Tanaka S. Analysis of case-cohort designs with binary outcomes: Improving efficiency using whole-cohort auxiliary information. Stat Methods Med Res. 2017;26(2):691–706. doi: 10.1177/0962280214556175. PubMed DOI

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models